News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,737 Results
Type
Article (57440)
Company Profile (660)
Press Release (693637)
Section
Business (218283)
Career Advice (2807)
Deals (37859)
Drug Delivery (108)
Drug Development (86268)
Employer Resources (179)
FDA (17592)
Job Trends (16205)
News (372020)
Policy (37232)
Tag
Academia (2902)
Alliances (53574)
Alzheimer's disease (1303)
Approvals (17494)
Artificial intelligence (132)
Bankruptcy (379)
Best Places to Work (12242)
Biotechnology (456)
Breast cancer (113)
Cancer (968)
Cardiovascular disease (89)
Career advice (2359)
Cell therapy (217)
Clinical research (67964)
Collaboration (344)
Compensation (174)
COVID-19 (2780)
Data (869)
Diabetes (146)
Diagnostics (6530)
Drug pricing (99)
Earnings (88240)
Employer resources (157)
Events (116938)
Executive appointments (252)
FDA (18047)
Funding (304)
Gene therapy (166)
GLP-1 (645)
Government (4861)
Healthcare (20194)
Infectious disease (2861)
Inflammatory bowel disease (113)
Interviews (496)
IPO (17080)
Job creations (4316)
Job search strategy (1988)
Layoffs (461)
Legal (9235)
Lung cancer (168)
Manufacturing (169)
Medical device (14108)
Medtech (14113)
Mergers & acquisitions (20770)
Metabolic disorders (406)
Neuroscience (1565)
NextGen Class of 2024 (7334)
Non-profit (4943)
Northern California (1213)
Obesity (238)
Opinion (226)
Patents (103)
People (60096)
Pharmaceutical (130)
Phase I (20980)
Phase II (29690)
Phase III (22393)
Pipeline (210)
Postmarket research (3022)
Preclinical (9080)
Radiopharmaceuticals (253)
Rare diseases (197)
Real estate (6616)
Regulatory (24445)
Research institute (2585)
Resumes & cover letters (462)
Southern California (1103)
Startups (3957)
United States (12334)
Vaccines (626)
Weight loss (195)
Date
Today (99)
Last 7 days (766)
Last 30 days (2899)
Last 365 days (37855)
2024 (32152)
2023 (42036)
2022 (53393)
2021 (58164)
2020 (57046)
2019 (50265)
2018 (38244)
2017 (35330)
2016 (35344)
2015 (41224)
2014 (35188)
2013 (30571)
2012 (32688)
2011 (33303)
2010 (31428)
Location
Africa (971)
Arizona (206)
Asia (43676)
Australia (7304)
California (2861)
Canada (1180)
China (219)
Colorado (126)
Connecticut (134)
Europe (96175)
Florida (398)
Georgia (108)
Illinois (345)
Indiana (193)
Kansas (100)
Maryland (560)
Massachusetts (2378)
Michigan (150)
Minnesota (262)
New Jersey (853)
New York (862)
North Carolina (751)
Northern California (1213)
Ohio (131)
Pennsylvania (758)
South America (1359)
Southern California (1103)
Texas (413)
Washington State (349)
751,737 Results for "actelion pharmaceuticals us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
October 3, 2024
·
8 min read
Deals
Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton
The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035.
March 26, 2024
·
4 min read
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.
May 30, 2024
·
4 min read
Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
December 8, 2023
·
2 min read
·
Tyler Patchen
BioCapital
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY ® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY ® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis .
December 7, 2023
·
9 min read
Business
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome
PANTHERx® Rare today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the U.S. Food and Drug Administration (FDA) and the first FDA-approved therapy specifically indicated for use in patients 12 years of age and older with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome.
April 29, 2024
·
2 min read
FDA
Pyros Pharmaceuticals Announces FDA Approval of VIGAFYDE™ (vigabatrin) as the First and Only Ready-to-Use Vigabatrin Oral Solution
Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved VIGAFYDE™, the only ready-to-use vigabatrin oral solution.
June 17, 2024
·
9 min read
Press Releases
Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
October 28, 2024
·
9 min read
Press Releases
Pixee Medical Inc. Announces Josh Hagel Appointed Vice President of Sales, US
October 29, 2024
·
3 min read
Press Releases
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
October 28, 2024
·
6 min read
1 of 75,174
Next